Are statins effective in preventing bioprosthetic aortic valve failure? a need for a prospective, randomized trial

Italian Heart Journal

Volumn 5, Issue 2, 2004, Pages 85-88

  Antonini Canterin, Francesco ^a   Popescu, Bogdan A ^b   Zuppiroli, Alfredo ^c   Nicolosi, Gian Luigi ^a  

^a S MARIA DEGLI ANGELI HOSPITAL   (Italy)

^b Prof Dr C C Iliescu Institute of Cardiovascular Diseases   (Romania)

^c S Maria Annunziata Hospital   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

AORTA VALVE; BIOPROSTHESIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DRUG EFFECT; EDITORIAL; HEART VALVE PROSTHESIS; HUMAN; PROSPECTIVE STUDY; PROSTHESIS FAILURE; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; VALVULAR HEART DISEASE;

AORTIC VALVE; BIOPROSTHESIS; HEART VALVE DISEASES; HEART VALVE PROSTHESIS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; PROSPECTIVE STUDIES; PROSTHESIS FAILURE; RANDOMIZED CONTROLLED TRIALS; TREATMENT OUTCOME;

EID: 4644236499     PISSN: 1129471X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Editorial

References (30)

1. Bloomfield P, Wheatley DJ, Prescott RJ, Miller HC. Twelve-year comparison of a Bjork-Shiley mechanical heart valve with porcine bioprosthesis. N Engl J Med 1991; 324: 573-9.
2. Hammermeister K, Sethi GK, Henderson WG, Grover FL, Oprian C, Rahimtoola S. Outcomes 15 years after valve replacement with a mechanical versus a bioprosthetic valve: final report of the Veterans Affairs Randomized Trial. J Am Coll Cardiol 2000; 36: 1152-8.
3. The United Kingdom Heart Valve Registry Report 1997. London: UK Heart Valve Registry, Imperial College School of Medicine, Hammersmith Hospital, 1999.
4. Treasure T. Rethink on biological aortic valves for the elderly. Lancet 1999; 354: 964-5.
5. Aronow WS, Ahn C, Kronzon I, Goldman ME. Association of coronary risk factors and use of statins with progression of mild valvular aortic stenosis in older persons. Am J Cardiol 2001; 88: 693-5.
6. Novaro GM, Tiong IY, Pearce GL, Lauer MS, Sprecher DL, Griffin BP. Effect of hydroxymethylglutaryl coenzyme A reductase inhibitors on the progression of calcific aortic stenosis. Circulation 2001; 104: 2205-9.
7. Bellamy MF, Pellikka PA, Klarich KW, Tajik AJ, Enriquez-Sarano M. Association of cholesterol levels, hydroxy-methylglutaryl coenzyme-A reductase inhibitor treatment, and progression of aortic stenosis in the community. J Am Coll Cardiol 2002; 40: 1723-30.
8. Farivar RS, Cohn LH. Hypercholesterolemia is a risk factor for bioprosthetic valve calcification and explantation. J Thorac Cardiovasc Surg 2003; 126: 969-76.
9. Nollert G, Miksch J, Kreuzer E, Reichart B. Risk factors for atherosclerosis and the degeneration of pericardial valves after aortic valve replacement. J Thorac Cardiovasc Surg 2003; 126: 965-8.
10. David TE, Ivanov J. Is degenerative calcification of the native aortic valve similar to calcification of bioprosthetic heart valves? J Thorac Cardiovasc Surg 2003; 126: 939-41.
11. Antonini-Canterin F, Zuppiroli A, Popescu BA, et al. Effect of statins on the progression of bioprosthetic aortic valve degeneration. Am J Cardiol 2003; 92: 1479-82.
12. Puvimanasinghe JP, Steyerberg EW, Takkenberg JJ, et al. Prognosis after aortic valve replacement with a bioprosthesis. Predictions based on meta-analysis and microsimulation. Circulation 2001; 103: 1535-41.
13. Tomazic BB, Edwards WD, Schoen FJ. Physicochemical characterization of natural and bioprosthetic heart valve calcific deposits: implications for prevention. Ann Thorac Surg 1995; 60 (Suppl): S322-S327.
14. Chanda J. Prevention of calcification of heart valve bioprostheses: an experimental study in rat. Ann Thorac Surg 1995; 60 (Suppl): S339-S342.
15. Mirzaie M, Meyer T, Schwartz P, Dalichau H. Preimplant ultrastructure and calcification tendency of various biological aortic valves. J Heart Valve Dis 2000; 9: 576-82.
16. Rao V, Jamieson E, Ivanov J, Armstrong S, David TE. Prosthesis-patient mismatch affects survival after aortic valve replacement. Circulation 2000; 102 (Suppl III): III5-III9.
17. Rahimtoola SH. Choice of prosthetic heart valve for adult patients. J Am Coll Cardiol 2003; 41: 893-904.
18. Grunkemeier GL, Bodnar E. Comparative assessment of bioprosthesis durability in the aortic position. J Heart Valve Dis 1995; 4: 49-55.
19. Otto CM, Kuusisto J, Reichenbach DD, Gown AM, O'Brien KD. Characterization of the early lesion of "degenerative" valvular aortic stenosis. Circulation 1994; 90: 844-53.
20. O'Brien KD, Reichenbach DD, Marcovina SM, Kuusisto J, Alpers CE, Otto CM. Apolipoproteins B, (a), and E accumulate in the morphologically early lesion of "degenerative" valvular aortic stenosis. Arterioscler Thromb Vasc Biol 1996; 16: 523-32.
21. Mohler ER 3rd. Are atherosclerotic processes involved in aortic-valve calcification? Lancet 2000; 356: 524-5.
22. Agmon Y, Khandheria BK, Meissner I, et al. Aortic valve sclerosis and aortic atherosclerosis: different manifestations of the same disease? Insights from a population-based study. J Am Coll Cardiol 2001; 38: 827-34.
23. Rajamannan NM, Subramaniam M, Springett M, et al. Atorvastatin inhibits hypercholesterolemia-induced cellular proliferation and bone matrix production in the rabbit aortic valve. Circulation 2002; 105: 2660-5.
24. Pohle K, Maffert R, Ropers D, et al. Progression of aortic valve calcification: association with coronary atherosclerosis and cardiovascular risk factors. Circulation 2001; 104: 1927-32.
25. Shavelle DM, Takasu J, Budoff MJ, Mao S, Zhao XQ, O'Brien KD. HMG-CoA reductase inhibitor (statin) and aortic valve calcium. Lancet 2002; 359: 1125-6.
26. Martinez-Gonzalez J, Badimon L. Human and porcine smooth muscle cells share similar proliferation dependence on the mevalonate pathway: implication for in vivo interventions in the porcine model. Eur J Clin Invest 1996; 26: 1023-32.
27. Martinez-Gonzalez J, Alfon J, Berrozpe M, Badimon L. HMG-CoA reductase inhibitors reduce vascular monocyte chemotactic protein-1 expression in early lesions from hypercholesterolemic swine independently of their effect on plasma cholesterol levels. Atherosclerosis 2001; 159: 27-33.
28. Farmer JA. Pleiotropic effects of statins. Curr Atheroscler Rep 2000; 2: 208-17.
29. Ridker PM, Rifai N, Pfeffer MA, Sacks F, Braunwald E. Long-term effects of pravastatin on plasma concentration of C-reactive protein. Circulation 1999; 100: 230-5.
30. Callister TQ, Raggi P, Cooil B, Lippolis NJ, Russo DJ. Effect of HMG-CoA reductase inhibitors on coronary artery disease as assessed by electron-beam computed tomography. N Engl J Med 1998; 339: 1972-8.